CAF化疗方案、曲妥珠单抗配合情绪干预治疗胃癌临床疗效评价

CAF Regimen,Trastuzumab Combined with Emotional Intervention on Patients with HER2-Positive Gastric Cancer

目的观察CAF化学治疗(简称化疗)方案、曲妥珠单抗配合情绪干预对人表皮生长因子受体2(HER-2)高表达(≥75%)胃癌患者疗效的影响。方法选取2014年1月至2015年8月收治的HER-2高表达(≥75%)胃癌患者96例,随机分为对照组和观察组,各48例。对照组患者给予常规CAF化疗方案治疗,观察组患者加用曲妥珠单抗治疗,两组患者均给予适当的情绪干预,疗程均为18周。比较两组患者的临床疗效,检测实体肿瘤长径及血清肿瘤标志物水平变化,记录不良反应。结果观察组总有效率为60.42%,高于对照组的41.67%,差异有统计学意义(P<0.05)。治疗后,观察组患者实体肿瘤长径较对照组减小(P<0.05),肿瘤标志物癌胚抗原(CEA)、糖蛋白199(CA199)、糖蛋白125(CA125)水平较对照组患者更低(P<0.05);两组患者不良反应未见显著性差异(P>0.05)。结论 CAF化疗方案、曲妥珠单抗配合情绪干预治疗HER-2高表达胃癌患者的临床疗效好,可降低肿瘤标记物水平,且不良反应少,值得临床推广。

Objective To observe the influence on the clinical efficacy of CAF regimen,trastuzumab combined with emotional intervention on patients with HER2- Positive Gastric Cancer. Methods 96 patients with HER- 2 positive gastric cancer（ ≥ 75%） from January2014 to August 2015 in the hospital were selected and randomly divided into the observation group and the control group,48 cases in each group. The control group was treated with CAF regimen,on this basis,the observation group was given trastuzumab. Both groups were given emotional intervention for 18 weeks. The clinical efficacies of the two groups were observed; the level of the tumor marker and length of solid tumor were detected; the adverse reactions were recorded. Results The total effective rate of the observation group was 60. 42%,which was higher than 41. 67% of the control group（ P〈0. 05）. After treatment,the length of solid tumor in the observation group was shorter than that in the control group（ P〈0. 05）,and the levels of the tumor marker CEA,CA199 and CA125 were lower than the control group（ P〈0. 05）. There was no significant difference in the adverse reactions between the two groups（ P〈0. 05）.Conclusion CAF regimen,trastuzumab combined with emotional intervention can achieve good clinical efficacy on patients with HER2- Positive Gastric Cancer by reducing the levels of tumor marker and with fewer adverse reactions,which is worthy of clinical promotion.